Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:06 PM
Ignite Modification Date:
2025-12-24 @ 9:06 PM
NCT ID:
NCT02769104
Eligibility Criteria:
Inclusion Criteria:
* provision of informed consent
* clinical stage IIA\~IIIC
* histologically proven HR+ invasive breast cancer
* women defined as postmenopausal according to NCCN guideline
* plan to accept the neoadjuvant (pre operational) chemotherapy treatment
Exclusion Criteria:
* clinical evidence of metastatic disease
* bilateral oophorectomy;
* radiation of the ovaries
* patients who, for whatever reason (e.g., confusion, infirmity, alcoholism), are unlikely to comply with trial requirements
* patients who accepted anti-cancer treatment before
* previous hormonal therapy as adjuvant treatment for non-cancer disease
* patients unwilling to stop taking any drug known to affect sex hormonal status, or in whom it would be inappropriate to stop
* previous history of invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin or carcinoma in situ of the cervix, adequately cone biopsied
* treatment with a non-approved or experimental drug during 1 month before entry into the study
* history of bleeding diathesis (i.e., Disseminated intravascular coagulation, clotting factor deficiency), or long term anticoagulant therapy (other than antiplatelet therapy and low dose warfarin)
* leukopenia and/or thrombocytopenia
* history of ocular fundus diseases
* history of thromboembolic diseases
* history of osteoporotic fractures
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
70 Years
Study:
NCT02769104
Study Brief:
Protocol Section:
NCT02769104